Groundbreaking Study on Personalized IVF Treatment in Frontiers in Endocrinology
- Yvonne Lundberg Giwercman
- May 12
- 1 min read
Dx4Life, a company at the forefront of personalized fertility diagnostics, announced today the publication of a significant scientific article in Frontiers in Endocrinology. The study, titled "FSH receptor N680S genotype-guided gonadotropin choice increases cumulative pregnancy and live birth rates after in vitro fertilization," was co-authored by Professor Yvonne Lundberg Giwercman, CEO of Dx4Life, and her research team.
The peer-reviewed article details findings from a clinical study demonstrating that tailoring hormone treatment for In Vitro Fertilization (IVF) based on a woman's genetic profile can significantly improve success rates. Specifically, the research identifies that carriers of a particular variant of the FSH receptor (FSHR) N680S gene respond optimally to urinary Follicle-Stimulating Hormone (uFSH), while others benefit more from recombinant FSH (rFSH). The study reported a notable increase in cumulative live birth rates when hormone therapy was matched to the patient's genotype.
Professor Lundberg Giwercman’s research underpins Dx4Life’s innovative oral swab test, which is designed to rapidly identify the most suitable hormone treatment for IVF patients based on their genetic makeup. This diagnostic tool aims to enhance precision in fertility care, potentially leading to a higher number of successful pregnancies and live births.
The full scientific article is available for review in Frontiers in Endocrinology:
Comments